Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of activated charcoal and polyethylene glycol (PEG) and is being evaluated by Assistance Publique - Hôpitaux de Paris for the treatment of severe acute poisoning. Activated charcoal is a highly porous adsorbent that binds to various toxic substances within the gastrointestinal tract, preventing their absorption into the systemic circulation. Polyethylene glycol is an osmotic macrogol used for whole bowel irrigation (WBI), which mechanically flushes the gastrointestinal tract to accelerate the elimination of unabsorbed toxins, particularly in cases involving large ingestions of solid-form medications or sustained-release formulations that may form pharmacobezoars. The combination aims to provide a more comprehensive decontamination strategy than standard care in intensive care patients requiring mechanical ventilation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on activated charcoal + polyethylene glycol.